{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:06:04Z","timestamp":1648764364256},"reference-count":38,"publisher":"Japan Society for Clinical Immunology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. J. Clin. Immunol.","Jpn.J.clin.Immun"],"published-print":{"date-parts":[[2013]]},"DOI":"10.2177\/jsci.36.162","type":"journal-article","created":{"date-parts":[[2013,6,29]],"date-time":"2013-06-29T22:45:54Z","timestamp":1372545954000},"page":"162-169","source":"Crossref","is-referenced-by-count":1,"title":["Development and pharmacological effects of anti-RANKL monoclonal antibody drug Denosumab"],"prefix":"10.2177","volume":"36","author":[{"given":"Masamichi","family":"TAKAMI","sequence":"first","affiliation":[{"name":"Department of Biochemistry, School of Dentistry, Showa University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1"},{"key":"2"},{"key":"3"},{"key":"4","unstructured":"4) Ivashkiv LB, Zhao B, Park-Min KH et al. : Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8. Ann N Y Acad Sci<\/i> 1237<\/b> : 88-94, 2011."},{"key":"5","unstructured":"5) Tarakida A, Higuchi T & Mizunuma H : Evidence of hormone replacement therapy for osteoporosis. Clinical Calcium<\/i> 18<\/b> : 1434-1441, 2008."},{"key":"6"},{"key":"7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Baron R : Osteoporosis in 2011 : Osteoporosis therapy-dawn of the post-bisphosphonate era. Nat Rev Endocrinol<\/i> 8<\/b> : 76-78, 2012.","DOI":"10.1038\/nrendo.2011.207"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Baron R, Ferrari S & Russell RG : Denosumab and bisphosphonates : different mechanisms of action and effects. Bone<\/i> 48<\/b> : 677-692, 2011.","DOI":"10.1016\/j.bone.2010.11.020"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Green LL : Antibody engineering via genetic engineering of the mouse : XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods<\/i> 231<\/b> : 11-23, 1999.","DOI":"10.1016\/S0022-1759(99)00137-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Lonberg N : Human antibodies from transgenic animals. Nat Biotechnol<\/i> 23<\/b> : 1117-1125, 2005.","DOI":"10.1038\/nbt1135"},{"key":"12","unstructured":"12) Jakobovits A, Amado RG, Yang X et al. : From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol<\/i> 25<\/b> : 1134-1143, 2007."},{"key":"13","unstructured":"13) Patel D, Balderes P, Lahiji A et al. : Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies<\/i> 16<\/b> : 127-136, 2007."},{"key":"14"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) van de Winkel JG & Anderson CL : Biology of human immunoglobulin G Fc receptors. J Leukoc Biol<\/i> 49<\/b> : 511-524, 1991.","DOI":"10.1002\/jlb.49.5.511"},{"key":"16","unstructured":"16) Kanamaru F, Iwai H, Ikeda T et al. : Expression of membrane-bound and soluble receptor activator of NF-κB ligand (RANKL) in human T cells. Immunol Lett<\/i> 94<\/b> : 239-246, 2004."},{"key":"17","unstructured":"17) Lacey DL, Boyle WJ, Simonet WS et al. : Bench to bedside : elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov<\/i> 11<\/b> : 401-419, 2012."},{"key":"18","unstructured":"18) Colucci S, Brunetti G, Rizzi R et al. : T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease : the role of the OPG\/TRAIL interaction. Blood<\/i> 104<\/b> : 3722-3730, 2004."},{"key":"19","unstructured":"19) Emery JG, McDonnell P, Burke MB et al. : Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem<\/i> 273<\/b> : 14363-14367, 1998."},{"key":"20","unstructured":"20) Lam J, Nelson CA, Ross FP et al. : Crystal structure of the TRANCE\/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest<\/i> 108<\/b> : 971-979, 2001."},{"key":"21","unstructured":"21) Ito S, Wakabayashi K, Ubukata O et al. : Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Biol Chem<\/i> 277<\/b> : 6631-6636, 2002."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Ye H, Arron JR, Lamothe B et al : Distinct molecular mechanism for initiating TRAF6 signalling. Nature<\/i> 418<\/b> : 443-447, 2002.","DOI":"10.1038\/nature00888"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Takayanagi H : Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol<\/i> 5<\/b> : 667-676, 2009.","DOI":"10.1038\/nrrheum.2009.217"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Takami M, Takahashi N, Udagawa N et al : Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts. Endocrinology<\/i> 141<\/b> : 4711-4719, 2000.","DOI":"10.1210\/en.141.12.4711"},{"key":"25"},{"key":"26","unstructured":"26) Kong YY, Yoshida H, Sarosi I et al. : OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature<\/i> 397<\/b> : 315-323, 1999."},{"key":"27","unstructured":"27) Kostenuik PJ, Nguyen HQ, McCabe J et al<\/i>. : Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. J Bone Miner Res<\/i> 24<\/b> : 182-195, 2009."},{"key":"28","unstructured":"28) Dougall WC, Glaccum M, Charrier K et al<\/i>. : RANK is essential for osteoclast and lymph node development. Genes Dev<\/i> 13<\/b> : 2412-2424, 1999."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) McClung MR, Lewiecki EM, Cohen SB et al : Denosumab in postmenopausal women with low bone mineral density. N Engl J Med<\/i> 354<\/b> : 821-831, 2006.","DOI":"10.1056\/NEJMoa044459"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Cummings SR, San Martin J, McClung MR et al : Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med<\/i> 361<\/b> : 756-765, 2009.","DOI":"10.1056\/NEJMoa0809493"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Bertoldo F, Tonini G, Vincenzi B et al : Medical oncology : zoledronic acid prevents bone loss in early-stage breast cancer. Nat Rev Clin Oncol<\/i> 6<\/b> : 191-192, 2009.","DOI":"10.1038\/nrclinonc.2009.24"},{"key":"32","unstructured":"32) Stopeck AT, Lipton A, Body JJ et al. : Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol<\/i> 28<\/b> : 5132-5139, 2010."},{"key":"33","unstructured":"33) Henry DH, Costa L, Goldwasser F et al. : Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol<\/i> 29<\/b> : 1125-1132, 2011."},{"key":"34","unstructured":"34) Fizazi K, Carducci M, Smith M et al. : Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet<\/i> 377<\/b> : 813-822, 2011."},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Brown JE & Coleman RE : Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol<\/i> 9<\/b> : 110-118, 2012.","DOI":"10.1038\/nrclinonc.2011.197"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Dore RK, Cohen SB, Lane NE et al<\/i> : Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis<\/i> 69<\/b> : 872-875, 2010.","DOI":"10.1136\/ard.2009.112920"},{"key":"37","unstructured":"37) Schwarz P, Rasmussen AQ, Kvist TM et al. : Paget's disease of the bone after treatment with Denosumab : a case report. Bone<\/i> 50<\/b> : 1023-1025, 2012."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kiechl S, Wittmann J, Giaccari et al : Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med<\/i> 19<\/b> : 358-363, 2013.","DOI":"10.1038\/nm.3084"}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/36\/3\/36_162\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T20:50:58Z","timestamp":1645908658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/36\/3\/36_162\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.36.162","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}